GT
BPMC

Glenmede Trust’s Blueprint Medicines BPMC Stock Holding History

Glenmede Trust’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$280K Buy
+3,162
New +$308K ﹤0.01% 1109
2020
Q4 		– Sell
-140
Closed -$12K – 1347
2020
Q3 		$12K Hold
140
– – ﹤0.01% 1801
2020
Q2 		$10K Sell
140
-1,544
-92% -$104K ﹤0.01% 1850
2020
Q1 		$134K Hold
1,684
– – ﹤0.01% 1317
2019
Q4 		$134K Buy
1,684
+79
+5% +$5.91K ﹤0.01% 1317
2019
Q3 		$117 Buy
1,605
+1,590
+10,600% +$137K ﹤0.01% 1350
2019
Q2 		$1 Buy
+15
New +$1.24K ﹤0.01% 2941

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Glenmede Trust's BPMC Position: Q1 2025 in Review

Glenmede Trust opened a new position in Blueprint Medicines (BPMC) in Q1 2025: 3,162 shares worth $280K. The stake represents ﹤0.01% of the portfolio and ranks #1109 among its holdings. This is a return to the name: Glenmede Trust previously reported a position in BPMC as recently as Q3 2020.

Glenmede Trust first reported a position in BPMC in Q2 2019 and has held it in 7 quarters since. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Glenmede Trust held 3,162 shares of Blueprint Medicines worth $280K as of Q1 2025.
  • Blueprint Medicines was a new Glenmede Trust position in Q1 2025.
  • Blueprint Medicines made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2025, its #1109 holding.
  • Glenmede Trust first reported a position in Blueprint Medicines in Q2 2019 and has held it in 7 quarters since.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.